A new legal clash in the cannabis industry is in focus after it was revealed which licensed producer (LP) is being targeted by an extraction firm in a new claim.
Last Friday (January 28), MediPharm Labs (TSX:LABS,OTCQX:MEDIF) informed investors that it had officially filed a statement of claim in the Ontario Superior Court of Justice targeting an undisclosed LP.
MediPharm Labs alleges it is owed a payment for “outstanding amounts,” which it calculates to be C$9.8 million. This missing payment is connected to a cannabis oil sale deal from February 2019.
According to the original agreement, the extraction firm had signed the agreement to supply HEXO, which was then not named, with its private label purified cannabis oil concentrates. The deal was set so HEXO would buy C$7.66 million worth of cannabis oil from MediPharm upfront while agreeing to the purchase of at least C$$27 million worth of product over a 12 month period starting in March 2019.
At the time, it was the fourth agreement of that kind that MediPharm had been able to sign with an LP.
“The contract is a supply agreement for which we had serious concerns and, in an effort to drive value for our shareholders, we attempted to work in good faith towards a resolution that was suitable for both parties. Unfortunately, these efforts were unsuccessful,” a HEXO spokesperson told BNN Bloomberg.
The LP confirmed that the deal was originally worked out between MediPharm and UP Cannabis, a division of Newstrike Brands, a company HEXO acquired in March 2019.
HEXO has not issued a press release confirming the suit, but it did tell BNN Bloomberg it will “vigorously defend” itself against the claim by MediPharm.
After its statement of claim against the Canadian LP was publicized, shares of MediPharm Labs took a hit on the open market. The company began dropping dramatically at the start of the trading week on Monday, and it closed that day at a price of C$3.03, a double-digit decline in value.
HEXO also saw a decline, although a smaller one. The company opened Tuesday’s (January 28) trading session in Toronto with an initial fall in value of over 3 percent for a price per share of C$1.30.
This isn’t the first time its acquisition of Newstrike has caused issues for HEXO and its shareholders. In November, the LP was forced to reveal that there were active unlicensed areas within Newstrike’s cannabis facility in Niagara, Ontario.
“The company notified Health Canada instantly, and the regulator was satisfied with HEXO management’s corrective actions,” HEXO said in a statement following the disclosure.
Leading Canadian cannabis companies are currently under pressure from the public, and HEXO has faced the ire of investors after being forced to adjust its revenue guidance recently.
After releasing disappointing results for its first 2020 fiscal quarter in December, HEXO was slammed by CIBC Capital Markets analyst duo John Zamparo and Krishna Ruthnum. They slapped the company with an “underperformer” rating and assigned it a price target of C$2.
The researchers also dropped their projections for sales from HEXO in its fiscal 2020 and 2021 years to C$75 million and $175 million, respectively.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.
Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.
The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement
Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination
Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising
Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.
In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.
Gage Cannabis Announces Exclusive Partnership With Blue River to Bring Award-Winning Cannabis Extracts to Michigan
Gage Growth Corp. (“Gage” or the “Company”) (CSE:GAGE), a leading high-quality craft cannabis brand and operator in Michigan, announced today that it has signed an agreement with Blue River™ Extracts & Terpenes (“Blue River™”) to bring the brand’s award-winning solventless technology and other trademark branded products to the state’s medical patients and cannabis consumers. The Company will have exclusive rights to Blue River™’s premium product offerings in Michigan.